Skip to main content
Clinical Trials/NCT04591132
NCT04591132
Unknown
N/A

Technology-based Analysis of Movement Disorders

University College, London0 sites50 target enrollmentNovember 1, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Movement Disorders
Sponsor
University College, London
Enrollment
50
Primary Endpoint
gait metrics
Last Updated
5 years ago

Overview

Brief Summary

Objectives: To generate pilot data to investigate the feasibility and the potential use in clinical practice of technology based objective measures of motor performances in patients affected by different movement disorders. To correlate kinematics findings with demographic and clinical details. Trial design and methods: Participants enrolled in prof. Bhatia's movement disorders clinic, will be classifies according to the main movement disorder, specifically, tremor, parkinsonism, dystonia, chorea, ataxia. In the study visit (one day only), they will undergo a clinical evaluation using the appropriate clinical scales (respectively, Fahn-Tolosa-Marin tremor rating scale, MDS-UPDRS Part III, Toronto Western Spasmodic Torticollis Rating Scale 2, Unified Hungtington Disease Rating scale and Scale for the Assessment and Rating of Ataxia) and a kinematic evaluation, using wearables and an infra-red and LED markers system. Then the protocol is concluded and they will continue the routine clinical follow-up

Registry
clinicaltrials.gov
Start Date
November 1, 2020
End Date
October 1, 2023
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • clinical diagnosis of parkinsonism and/or dystonia and/or tremor due to:
  • idiopatic parkinson's disease
  • atypical parkinsonism
  • sporadic or inherited/genetic dystonia
  • young-onset Parkinson's disease
  • Ataxia syndrome
  • Choereic syndrome
  • Essential tremor
  • Dystonic tremor
  • 18 to 80 years of age

Exclusion Criteria

  • Change in pharmacological therapy in the last 3 months.
  • Participated in a clinical drug trial up to 3 months before inclusion into the present study
  • Orthopaedical comorbidities affecting gait or posture.
  • Cognitive deficit

Outcomes

Primary Outcomes

gait metrics

Time Frame: up to 6 weeks after enrolment

gait cycles measures (step length, phase duration, number of steps) practice of technology based objective measures of motor performances in patients affected by different movement disorders, to objectively evaluate the disease burden, the efficacy of therapeutic interventions and having a deeper phenotyping of motor disabilities.

neck ROM

Time Frame: up to 6 weeks after enrolment

range of motion of the neck in x,y and z axis

bradykinesia evaluation

Time Frame: up to 6 weeks after enrolment

amplitude of repeated limb movements over time

tremor peak frequence

Time Frame: up to 6 weeks after enrolment

fourier analysis for peak frequence of tremor

Secondary Outcomes

  • correlation with UPDRS gait Item(up to 6 weeks after enrolment)

Similar Trials